Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.
Xbrane Biopharma AB announced the inclusion of the first patient in the pivotal clinical trial for Xdivane, a nivolumab biosimilar candidate. This trial, sponsored by Intas Pharmaceuticals Ltd, is crucial for regulatory approval and aims to coincide with the Loss of Exclusivity of the reference product. The initiation of this trial has triggered a €2 million milestone payment to Xbrane, highlighting the potential market impact of Xdivane, which targets a growing market for immune-oncology drugs.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK11.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology aimed at reducing production costs. The company focuses on biosimilar candidates with a portfolio targeting significant market opportunities, including a lead candidate, Ximluci®, which has received market authorization in Europe. Xbrane is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 167,943
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK220.5M
See more data about XBRANE stock on TipRanks’ Stock Analysis page.